Patents by Inventor Asahi Kawana
Asahi Kawana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167073Abstract: A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.Type: ApplicationFiled: April 15, 2021Publication date: June 1, 2023Applicant: Teijin Pharma LimitedInventors: Sakae SUGIYAMA, Takuya YOKOSAKA, Kunio MINAMIZONO, Asahi KAWANA, Toshiyuki KANEKO, Akinobu MARUYAMA, Kosuke SASAKI, Shinnosuke HOSODA, Masaki KOSHIMIZU, Susumu TAKEUCHI, Kenta KATO, Nagasree CHAKKA, Brett M. JOHNSON, Ryan D. WHITE, Wei ZHAO
-
Patent number: 10301300Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: May 1, 2018Date of Patent: May 28, 2019Assignee: TEIJIN LIMITEDInventors: Takashi Shirakura, Yoshimasa Takahashi, Asahi Kawana, Chikashi Kanazawa
-
Patent number: 10179780Abstract: There are provided: 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid, a sodium salt thereof and crystals of these, useful as a therapeutic agent and a prophylactic agent for gout, hyperuricemia and the like, and a method for producing the same.Type: GrantFiled: July 29, 2015Date of Patent: January 15, 2019Assignee: Teijin Pharma LimitedInventors: Asahi Kawana, Hisae Nozato, Chikashi Kanazawa
-
Publication number: 20180244665Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: May 1, 2018Publication date: August 30, 2018Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
-
Patent number: 9815826Abstract: There are provided crystals of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid which is useful as a therapeutic agent or prophylactic agent for gout, hyperuricemia and the like.Type: GrantFiled: July 29, 2015Date of Patent: November 14, 2017Assignee: Teijin Pharma LimitedInventors: Asahi Kawana, Yuki Miyazawa
-
Publication number: 20170247364Abstract: There are provided: 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid, a sodium salt thereof and crystals of these, useful as a therapeutic agent and a prophylactic agent for gout, hyperuricemia and the like, and a method for producing the same.Type: ApplicationFiled: July 29, 2015Publication date: August 31, 2017Applicant: TEIJIN PHARMA LIMITEDInventors: Asahi KAWANA, Hisae NOZATO, Chikashi KANAZAWA
-
Publication number: 20170217948Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 29, 2015Publication date: August 3, 2017Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
-
Publication number: 20170210735Abstract: There are provided crystals of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid which is useful as a therapeutic agent or prophylactic agent for gout, hyperuricemia and the like.Type: ApplicationFiled: July 29, 2015Publication date: July 27, 2017Applicant: TEIJIN PHARMA LIMITEDInventors: Asahi KAWANA, Yuki MIYAZAWA
-
Patent number: 9617240Abstract: Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and R1 have the meaning set forth in claim 1].Type: GrantFiled: March 28, 2014Date of Patent: April 11, 2017Assignee: Teijin Pharma LimitedInventors: Asahi Kawana, Chikashi Kanazawa, Masayuki Tera, Yoshimasa Takahashi, Mariko Imazeki, Hiroyuki Takahashi, Akira Tanokura
-
Patent number: 9388174Abstract: The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.Type: GrantFiled: January 30, 2014Date of Patent: July 12, 2016Assignee: Teijin Pharma LimitedInventors: Asahi Kawana, Chikashi Kanazawa, Yoshimasa Takahashi, Takashi Shirakura
-
Publication number: 20160039784Abstract: Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and R1 have the meaning set forth in claim 1].Type: ApplicationFiled: March 28, 2014Publication date: February 11, 2016Applicant: TEIJIN PHARMA LIMITEDInventors: Asahi KAWANA, Chikashi KANAZAWA, Masayuki TERA, Yoshimasa TAKAHASHI, Mariko IMAZEKI, Hiroyuki TAKAHASHI, Akira TANOKURA
-
Publication number: 20150376174Abstract: The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.Type: ApplicationFiled: January 30, 2014Publication date: December 31, 2015Applicant: TEIJIN PHARMA LIMITEDInventors: Asahi KAWANA, Chikashi KANAZAWA, Yoshimasa TAKAHASHI, Takashi SHIRAKURA
-
Publication number: 20090076120Abstract: Two crystal forms of (R)-3-[2-(2-amino-5-trifluoromethoxybenzamido)acetamido]-1-(6-methylindol-3-ylmethyl)pyrrolidine which exhibit specific X-ray powder diffraction patterns or infrared absorption spectra, amorphous form thereof, a pharmaceutical composition containing the crystal or amorphous form as an active ingredient, as well as methods for preparing them are provided.Type: ApplicationFiled: April 6, 2006Publication date: March 19, 2009Applicant: TEIJIN PHARMA LIMITEDInventors: Takumi Takeyasu, Yoshinori Sato, Asahi Kawana, Yuji Takahashi, Yuji Ishikawa, Kaoru Suda
-
Publication number: 20070249847Abstract: A production method of an acetamidopyrrolidine derivative or a salt thereof comprising the reaction steps represented by the following formula: wherein R1 represents a hydrogen atom or a C1-C6 alkyl group; R13, R14, R15 and R16 each represent independently a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 haloalkyl group or a C1-C6 haloalkoxy group; and R21 represents an ester-type protecting group.Type: ApplicationFiled: June 13, 2005Publication date: October 25, 2007Applicant: TEIJIN PHARMA LIMITEDInventors: Asahi Kawana, Takumi Takeyasu, Atsuo Hazato
-
Publication number: 20070073064Abstract: There is provided an industrial production method of an aminopyrrolidine derivative having chemokine receptor antagonist activity represented by the following formula, a synthetic intermediate thereof and a production method thereof: wherein R11 is H, C1-C6 alkyl or C2-C7 alkanoyl; R12, R14, R15, R16 and R17 are H, halogen, optionally halogenated C1-C6 alkyl, optionally halogenated C1-C6 alkoxy, hydroxyl or C2-C7 alkoxycarbonyl; R23, R24, R25 and R26 are H, halogen, optionally halogenated C1-C6 alkyl, optionally halogenated C1-C6 alkoxy or hydroxyl; and R3 is H or C1-C6 alkyl.Type: ApplicationFiled: October 7, 2004Publication date: March 29, 2007Applicant: TEIJIN PHARMA LIMITEDInventors: Takumi Takeyasu, Yoshinori Sato, Minoru Imai, Mitsuru Sakai, Kenji Manabe, Yoshiyuki Matsumoto, Susumu Takeuchi, Asahi Kawana, Masahiro Koga, Mitsuharu Asahita